Dashboard
1
High Management Efficiency with a high ROE of 15.35%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of -8.97
3
Healthy long term growth as Net Sales has grown by an annual rate of 83.05% and Operating profit at 84.23%
4
Flat results in Mar 25
5
With ROE of 52.40%, it has a fair valuation with a 13.23 Price to Book Value
6
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
7
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
SEK 21,425 Million (Small Cap)
25.00
NA
0.00%
-0.93
52.40%
10.52
Revenue and Profits:
Net Sales:
392 Million
(Quarterly Results - Jun 2025)
Net Profit:
97 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.78%
0%
-5.78%
6 Months
62.3%
0%
62.3%
1 Year
75.59%
0%
75.59%
2 Years
37.79%
0%
37.79%
3 Years
7.47%
0%
7.47%
4 Years
182.65%
0%
182.65%
5 Years
232.02%
0%
232.02%
BioArctic AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
83.05%
EBIT Growth (5y)
84.23%
EBIT to Interest (avg)
-8.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.50
Tax Ratio
3.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
17.86%
ROE (avg)
15.35%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
13.23
EV to EBIT
19.58
EV to EBITDA
19.58
EV to Capital Employed
186.26
EV to Sales
13.46
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
951.43%
ROE (Latest)
52.40%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
392.10
1,289.60
-69.60%
Operating Profit (PBDIT) excl Other Income
210.70
1,147.50
-81.64%
Interest
16.10
14.20
13.38%
Exceptional Items
0.00
0.00
Consolidate Net Profit
96.60
1,021.50
-90.54%
Operating Profit Margin (Excl OI)
537.20%
889.80%
-35.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -69.60% vs 1,174.31% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -90.54% vs 3,342.86% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
257.40
616.00
-58.21%
Operating Profit (PBDIT) excl Other Income
-205.20
275.10
-174.59%
Interest
0.00
0.40
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-177.10
229.20
-177.27%
Operating Profit Margin (Excl OI)
-892.20%
416.70%
-130.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -58.21% vs 169.82% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -177.27% vs 2,146.43% in Dec 2023
About BioArctic AB 
BioArctic AB
Pharmaceuticals & Biotechnology
BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.
Company Coordinates 
Company Details
Warfvinges vag 35 , STOCKHOLM None : 112 51
Registrar Details






